The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $44.64

Today's change+0.44 +1.00%
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

GW Pharmaceuticals PLC

Nasdaq: GWPH
Last

(U.S.) $44.64

Today's change+0.44 +1.00%
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

GW Pharmaceuticals PLC up (U.S.)$0.44

GW Pharmaceuticals PLC closed up Friday by (U.S.)$0.44 or 1.00% to (U.S.)$44.64. Although unchanged over the last five days, shares are down 35.71% for the last year to date. This security has underperformed the S&P 500 by 30.85% during the last year.

Key company metrics

  • Open(U.S.) $44.62
  • Previous close(U.S.) $44.20
  • High(U.S.) $44.98
  • Low(U.S.) $42.35
  • Bid / Ask-- / --
  • YTD % change-35.71%
  • Volume214,047
  • Average volume (10-day)371,238
  • Average volume (1-month)373,844
  • Average volume (3-month)350,580
  • 52-week range(U.S.) $39.93 to (U.S.) $133.98
  • Beta--
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.10
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-156.14%

Although this company's net profit margin is negative, it is above the industry average and implies that GW Pharmaceuticals PLC is operating more effectively than other companies in the industry.
Company Books

S&P TSX2.43%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue6968
Total other revenue--------
Total revenue6968
Gross profit5867
Total cost of revenue1111
Total operating expense24331612
Selling / general / administrative5341
Research & development25211515
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-19-25-9-4
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-19-25-9-4
Income after tax-12-21-7-3
Income tax, total-6-3-2-1
Net income-12-21-7-3
Total adjustments to net income--------
Net income before extra. items-12-21-7-3
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-12-21-7-3
Inc. avail. to common incl. extra. items-12-21-7-3
Diluted net income-12-21-7-3
Dilution adjustment--------
Diluted weighted average shares261251237237
Diluted EPS excluding extraordinary itemsvalue per share-0.05-0.09-0.03-0.01
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.05-0.09-0.03-0.01